Acasti Pharma Inc. (Acasti) is engaged in developing a product portfolio of long-chain omega-3 phospholipids. Acasti is a majority owned subsidiary of Neptune Technologies and Bioressources Inc. (Neptune). The Company has one operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Companyâ€™s product portfolio includes concentrated phospholipids which functionalize eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Acasti is the producer of anti-dyslipidemic prescription drugs (CaPre), medical foods (Onemia) and over-the-counter (OTC) products (Vectos). During the fiscal year ended February 28, 2011 (fiscal 2011), the Company has completed the development and launched medical food, Onemia.
|Jerald Wenker||Chairman of the Board|
|Andre Godin||Interim President and Chief Executive Officer|
|Pierre Lemieux||Chief Operating Officer|
|Harlan Waksal||Executive Executive Vice President - Business and Scientific Affairs, Director|
|Tina Sampalis||Chief Global Strategy Officer|